Page last updated: 2024-11-05

melarsen oxide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Melarsen oxide is an organic arsenical compound that was initially synthesized as a potential treatment for African trypanosomiasis. It was later found to be effective against other parasitic infections, such as leishmaniasis and schistosomiasis. Melarsen oxide is a potent inhibitor of trypanothione reductase, an enzyme essential for the survival of trypanosomes. This inhibition disrupts the parasite's redox balance and leads to its death. Melarsen oxide was explored as a therapeutic option due to its effectiveness against various parasitic diseases, particularly trypanosomiasis, which is a life-threatening illness. However, its clinical use is limited due to its toxicity and the emergence of drug resistance. Ongoing research investigates melarsen oxide and its analogs to understand its mechanism of action, explore potential therapeutic applications, and develop safer and more effective anti-parasitic drugs.'

melarsen oxide: inhibits glutathione reductase [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID30830
CHEMBL ID313792
SCHEMBL ID1266080
MeSH IDM0130450

Synonyms (35)

Synonym
melamine, (p-arsenosophenyl)-
(p-arsenosophenyl)melamine
CHEMBL313792
nsc-34642
nsc34642
21840-08-4
antineoplastic-34642
ai3-51158
1,3,5-triazine-2,4,6-triamine, n-(4-arsenosophenyl)-
1,3,5-triazine-2,4,6-triamine, n-(4-arsenosophenyl)-, dihydrate
melarsenoxyd
n-(p-arsenosophenyl)-1,3,5-triazine-2,4,6-triamine
n(sup 2)-(p-arsenosophenyl)melamine
melamine, n(sup 2)-(p-arsenosophenyl)-
einecs 244-612-8
n-(4-arsenosophenyl)-1,3,5-triazine-2,4,6-triamine
brn 0024579
melox
p-(2,4-diamino-s-triazinyl-6)aminophenylarsine oxide
friedheim 2065
nsc 34642
melarsen oxide
2-n-(4-arsorosophenyl)-1,3,5-triazine-2,4,6-triamine
3177 r.p.
2xh88ixe7w ,
4-26-00-01291 (beilstein handbook reference)
unii-2xh88ixe7w
2-(p-arsenosoanilino)-4,6-diamino-s-triazine
M-1150
1,3,5-triazine-2,4,6-triamine, n2-(4-arsenosophenyl)-
SCHEMBL1266080
DTXSID30176247
1,3,5-triazine-2,4,6-triamine, n-(4-arsenosophenyl)- (9ci)
Q27255764
n2-(4-arsenosophenyl)-1,3,5-triazine-2,4,6-triamine
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID215354In Vitro Growth Inhibitory Value against K269 Strain of Trypanosoma brucei. 2001Journal of medicinal chemistry, Jan-04, Volume: 44, Issue:1
Terminally alkylated polyamine analogues as chemotherapeutic agents.
AID215355In Vitro Growth Inhibitory Value against LAB 110 Strain of Trypanosoma brucei2001Journal of medicinal chemistry, Jan-04, Volume: 44, Issue:1
Terminally alkylated polyamine analogues as chemotherapeutic agents.
AID215353In Vitro Growth Inhibitory Value against K243 Strain of Trypanosoma brucei. 2001Journal of medicinal chemistry, Jan-04, Volume: 44, Issue:1
Terminally alkylated polyamine analogues as chemotherapeutic agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (34)

TimeframeStudies, This Drug (%)All Drugs %
pre-199010 (29.41)18.7374
1990's11 (32.35)18.2507
2000's11 (32.35)29.6817
2010's2 (5.88)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.98

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.98 (24.57)
Research Supply Index3.58 (2.92)
Research Growth Index4.26 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.98)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (2.86%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other34 (97.14%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]